Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | STS | P08842 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL12180048 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL14373308 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL4896486 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL7004654 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223196 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL13123063 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL23743979 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Epiestriol SCHEMBL221084 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL8941750 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL2001122 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20190180877-A1 | ESTROGEN METABOLITE LEVELS AND CYP1B1 POLYMORPHISMS IN LUNG CANCER DIAGNOSIS, PROGNOSIS, AND RISK ASSESSMENT | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2019-06-13 | — | — | US | claimed |
| EP-2807482-B1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEV PTE LTD (SG) | 2018-03-14 | — | — | EP | claimed |
| US-9874575-B2 | Analysis of estradiol and analytes with phenolic OH using labeling chemistry and LC-MSMS workflow | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-01-23 | — | — | US | claimed |
| US-20150051111-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2015-02-19 | — | — | US | claimed |
| US-20140363406-A1 | ESTROGEN METABOLITE LEVELS AND CYP1B1 POLYMORPHISMS IN LUNG CANCER DIAGNOSIS, PROGNOSIS, AND RISK ASSESSMENT | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-12-11 | — | — | US | claimed |
| EP-2807482-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | Dh Technologies Development Pte. Ltd. (SG) | 2014-12-03 | — | — | EP | claimed |
| WO-2012032529-A1 | STEREOSELECTIVE REDUCTION OF ALPHA-HYDROXYKETONE | RELIANCE LIFE SCIENCES PVT. LTD (IN) | 2012-03-15 | — | — | WO | claimed |
| US-7951890-B2 | Using epichlorohydrin to form gel; pulverization; mixing with buffer solution and hydrolases; stirring; centrifuging | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-31 | — | — | US | claimed |
| US-20100312137-A1 | Ovulation Cycle Monitoring and Management | GILMOUR ROBERT | 2010-12-09 | — | — | US | claimed |
| US-20080207931-A1 | Solid-Phase Extraction Method of Steroid Hormones by Entrapped Beta-Cyclodextrin Polymers | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-08-28 | — | — | US | claimed |
| EP-1952162-A2 | OVULATION CYCLE MONITORING AND MANAGEMENT | MANAWATU BIOTECH INVESTMENTS LTD. (MBIL) (NZ) | 2008-08-06 | — | — | EP | claimed |
| WO-2007049157-A2 | OVULATION CYCLE MONITORING AND MANAGEMENT | MANAWATU BIOTECH INVESTMENTS LTD. (MBIL) (US) | 2007-05-03 | — | — | WO | claimed |
| US-6476196-B1 | Estrogen receptor ligands | KARA BIO AB (SE) | 2002-11-05 | — | — | US | claimed |
| EP-1149838-A1 | Estriol substantially free of 16alpha, 17alpha-estra-1,3,5(10)-triene-3,16,17-triol | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2001-10-31 | — | — | EP | claimed |
| US-4592869-A | Selective acylation process | AKTIEBOLAGET LEO (SE) | 1986-06-03 | — | — | US | claimed |
| EP-0138153-A2 | A selective acylation process | AB LEO (SE) | 1985-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ESR1 1524/4885ESR2 409/4885LMNA 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.